There are ongoing discussions of the possibility of replacing the thorough QT (TQT) study with QT assessment in early phase clinical studies and the subject is currently under consideration by the International Conference of Harmonisation E14 Discussion Group. For small molecules, early studies are typically performed in healthy subjects with a good range of doses of the new chemical entity (NCE), and they often generate plasma concentrations of the parent compound and metabolites in substantial excess of the therapeutic levels later determined in development in patients. Phase 1 studies are often conducted in clinical units with the same level of strict experimental control as TQT studies and are therefore well suited to generate electrocardiogram (ECG) data of good quality using modern techniques with serial ECGs. If the effects of an NCE on ECG parameters can be evaluated using data from these studies with the same high level of confidence as from a TQT study, this would represent a more resource-efficient approach and would also come with the advantage of learning about adverse ECG effects early in clinical development.
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The power of a study to exclude small ECG effects can be greatly enhanced by using exposure response (ER) analysis (ie, by relating potential effects to a broad range of plasma concentrations of the drug). ER analysis has been extensively used by the FDA in the evaluation of ECG data from TQT and other studies and has played a major role in the regulatory decision making. 1 Definitive assessment of an NCE's potential to cause relatively small ECG effects based on data from early-phase clinical studies relies on the use of ER analysis, replacing the E14-mandated approach of testing the effect separately at each postdosing timepoint. It is therefore of great importance to discuss and obtain wide agreement on how to define the absence of a QT effect using this approach.
A prospective study was recently designed and conducted in close collaboration between FDA, industry, and cardiac safety experts to validate the concept of detecting and excluding druginduced QT effects by applying ER analysis to ECG data from a small, phase 1 study. 2 The study detected the QT effects of 5 marketed drugs with known QT effect and excluded significant effects for 1 drug with a previous negative TQT study. The criterion for ''negative QT assessment'' in that study was based on ER analysis and was designed to exclude a QT effect of clinical concern, as previously suggested 3 :
The upper bound of the 2-sided 90% confidence interval of the predicted placebo-adjusted change-from-baseline QTc (DQTc) should be below 10 ms at the highest clinically relevant plasma concentrations of the drug.
The criterion above is based on a tiered approach with 2 steps: (1) ECG data are generated from early-phase clinical study(ies), which generally examine the full range of doses that could later be used in clinical studies. In most cases, those levels will exceed the doses ultimately used in trials. Figure 1A shows the QT effect seen in a SAD study. 4 The results are most useful if the highest levels do indeed exceed the levels seen with therapeutic doses, but the ER relationship provides an early indication of the likelihood of a significant QT effect. Using ER analysis at this stage identifies a range of concentrations that will not produce a QTc prolongation of concern and provides early information on what higher doses are likely to do. (2) Only later in development, when the pharmacokinetic (PK) profile of the NCE has been well characterized in the targeted patient population, can it become known that the achieved plasma concentrations in the phase 1 study in fact exceed the highest possible therapeutic levels (ie, those observed in worst-case-scenario patients with impaired clearance of the drug). Confidence in the absence of an effect will be higher the more the phase 1 exposure exceeds those concentrations ultimately deemed clinically relevant.
Different criteria for a negative QT assessment were presented at a DIA Cardiac Safety meeting in 2012 and are now published in this journal as part of a comparison between the E14 approach of analyzing the QT effect separately at each postdosing timepoint and the predicted effect using ER analysis from more than 200 TQT studies. 5 The authors concluded that the concordance between the 2 approaches on data from TQT studies, both in terms of detecting and of excluding a QT effect, is good. Furthermore, they proposed that if the slope of the ER relationship is statistically significantly positive, then something further is necessary. They suggested this could be a TQT study, but we believe that with an adequately characterized ER relationship, it will usually be possible to exclude clinically relevant QT prolongation based on the predicted QT effect at the highest concentration that could be attained in practice (or perhaps some multiple of that concentration to account for unexpected outliers). In Figure 1B , a constructed example is shown in which the slope of the ER is significant but the predicted effect at the highest plasma concentrations that could occur is well below the threshold of concern (10 ms). Thus, with the definition we propose, the example in Figure 1B would also constitute a negative QT assessment, without the need for another clinical study.
Extensive experience with QT-prolonging drugs demonstrates that, with few exceptions, the effect on the QT interval is directly related to plasma levels of the drug or main metabolites, a finding confirmed by the study by Zhang and coauthors in which indisputable hysteresis was observed in only 1 of 277 TQT studies. 5 In our view, it therefore makes sense to focus on QT effects in relation to plasma concentrations of the drug, rather than by timepoint without consideration of the pharmacology. A wider role for ER analysis in the assessment of druginduced ECG effects is well justified. Sufficient experience with ER analysis has now been gained to consider its wider acceptance as an alternative to the TQT study, and the definition of criteria for a negative QT assessment with this approach Figure 1. (A) The graph illustrates the exposure response analysis of data from a standard single-ascending dose study with 6 dose groups (2 on placebo, 6 on active in each; doses from 5 to 600 mg) in 48 healthy subjects. The predicted QT effect using ER analysis is shown with the 90% CI (solid black line with gray-shaded area) across the range of observed plasma concentrations in the study. The vertical bars show the observed placebo-corrected DQTcF with 90% CI within each plasma concentration decile. This way of displaying the data allows a visual assessment of the ER model fit to the observed data. As shown by the upper bound of the 90% CI, a drug-induced effect on the QTc interval exceeding 10 ms could be excluded throughout the observed range of plasma concentrations. Whether this constitutes a negative QT assessment can only be determined later in clinical development, when the PK profile and therefore the highest achievable plasma concentrations in patients are known. (B) A constructed example of ER analysis of data from an early-phase clinical study with observed plasma concentrations of the NCE up to 1000 ng/mL. The predicted QT effect is shown with 90% CI, and the horizontal line at the bottom of the graph represents plasma concentrations deciles. The range of plasma concentrations seen in the targeted patient population at the highest indicated dose, including patients with the highest levels based on impaired clearance of the drug, is shown as the shaded area. In this example, there is a close relationship of plasma concentrations and the QT effect, with a statistically significant slope, but the predicted effect at clinically relevant plasma concentrations is well below 10 ms. Figure 1A 
